{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:59:16Z","timestamp":1787025556187,"version":"build-2736575974"},"reference-count":16,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HeartDrug Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: This study aimed to determine the impact of central adjudication of site-reported events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in addition to aspirin within the frame of indication-seeking The PLATelet Inhibition and Clinical Outcomes (PLATO) trial. Adjudication in randomized outcome-driven trials is supposed to maintain integrity by applying uniform rules for the quality assessment of clinical events. Some preliminary data suggest an imbalance between central and site diagnoses in PLATO. We gained access to the Food and Drug Administration (FDA)-issued adjudication dataset and analyzed the evidence. Methods: Death, myocardial infarction (MI), stroke\/ transient ischemic attack (TIA), bleeding, arterial thrombotic events, and cardiac ischemic events underwent central adjudication. We assessed geography, timing, impact of disagreements, and primary endpoint composition. Results: Among 18,624 trial enrollees, 10,704 central adjudications occurred across 7171 patients in 43 countries. There were 938 deaths, 2751 cases of MI, 359 strokes\/TIAs, 2680 cardiac events, 130 thrombotic events, and 3782 bleeding events. The match occurred for 5451 events, while mismatches favoring clopidogrel (n = 2535) or ticagrelor (n = 2706) (p = 0.79) were common for major (n = 1797), moderate (n = 942), or minor (n = 735) disagreements. The central decision prevailed in 2945 cases. There was a significant (HR = 0.84; 95% confidence intervals (CI): 0.75\u20130.95; p = 0.004) adjudication delay in the 2007\u20132008 events but finalized in 2009. Ticagrelor was significantly less favored in 2009 than in 2007\u20132008 (HR = 1.19; 95% CI: 1.05\u20131.34; p = 0.005). There was a remarkably consistent match for bleeding adjudication (HR = 1.02; 95% CI: 0.83\u20131.25; p = 0.859) between treatment arms. The primary endpoint in the PLATO trial exhibited highly significant disagreement favoring ticagrelor for vascular death (HR = 2.02; 95% CI: 1.1\u20133.64; p = 0.019); MI (HR = 2.31; 95% CI: 2.79\u201343.94; p = 0.034); stroke (HR = 1.37; 95% CI: 2.66\u201363.28; p = 0.036); total events (HR = 2.51; 95% CI: 1.86\u20133.39; p = 0.01). Conclusion: Central adjudication in the PLATO trial was delayed and impacted the primary endpoint by inflating the ticagrelor benefit, resulting in drug approval. The regulatory authorities should consider independent audits when unblinding is suspected in the indication-seeking clinical trials.<\/jats:p>","DOI":"10.31083\/rcm36733","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T06:56:58Z","timestamp":1745909818000},"source":"Crossref","is-referenced-by-count":4,"title":["Impact of Central Event Adjudication on the PLATO Trial Results"],"prefix":"10.31083","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6597-5445","authenticated-orcid":true,"given":"Victor L.","family":"Serebruany","sequence":"first","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"HeartDrug Research LLC, West Friendship, MD 21294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4548-7353","authenticated-orcid":true,"given":"Wendy","family":"Ziai","sequence":"first","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-7098","authenticated-orcid":true,"given":"Hector A.","family":"Cabrera-Fuentes","sequence":"first","affiliation":[{"name":"R&D Group, Vice Presidency for Scientific Research and Innovation, Imam Abdulrahman bin Faisal University (IAU), 31441 Dammam, Saudi Arabia"},{"name":"UNAM-UABJO Research Center, Universidad Aut\u00f3noma Benito Ju\u00e1rez de Oaxaca, 68120 Oaxaca, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Pokov","sequence":"first","affiliation":[{"name":"HeartDrug Research LLC, West Friendship, MD 21294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Hwang","sequence":"first","affiliation":[{"name":"HeartDrug Research LLC, West Friendship, MD 21294, USA"},{"name":"Department of Pharmacology, University of Maryland, College Park, MD 20742, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-1624","authenticated-orcid":true,"given":"Thomas","family":"Marciniak","sequence":"first","affiliation":[{"name":"Physician, retired from FDA, Alexandria, VA 22314, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Held C. When do we need clinical endpoint adjudication in clinical trials? Upsala Journal of Medical Sciences. 2019; 124: 42\u201345.","DOI":"10.1080\/03009734.2018.1516706."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, et al. Do we need to adjudicate major clinical events? Clinical Trials (London, England). 2008; 5: 56\u201360.","DOI":"10.1177\/1740774507087972."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Godolphin PJ, Bath PM, Algra A, Berge E, Chalmers J, Eliasziw M, et al. Cost-benefit of outcome adjudication in nine randomised stroke trials. Clinical Trials (London, England). 2020; 17: 576\u2013580.","DOI":"10.1177\/1740774520939231."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2009; 361: 1045\u20131057.","DOI":"10.1056\/NEJMoa0904327."},{"key":"ref5","unstructured":"Center for Drug Evaluation and Research. Approval Package for: Application number: NDA 22-433\/S015. The FDA ticagrelor Secondary Review. 2015. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/022433orig1s015.pdf (Accessed: 1 July 2023)."},{"key":"ref6","unstructured":"Center for Drug Evaluation and Research. The FDA Ticagrelor Review of Complete Response. 2011. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022433Orig1s000TOC.cfm (Accessed: 21 October 2023)."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Serebruany V, Tanguay JF, Benavides MA, Cabrera-Fuentes H, Eisert W, Kim MH, et al. Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Journal of Therapeutics. 2020; 27: e563\u2013e572.","DOI":"10.1097\/MJT.0000000000001286."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Serebruany V, Tanguay JF, Cabrera-Fuentes HA, Gurvich ML, Marciniak T. Impact of the reporting source on Platelet Inhibition and Treatment Outcomes (PLATO) trial deaths. Discoveries (Craiova). 2023; 11: e174.","DOI":"10.15190\/d.2023.13."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Serebruany VL, Fortmann SD. International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic? Expert Review of Cardiovascular Therapy. 2015; 13: 867\u2013869.","DOI":"10.1586\/14779072.2015.1063419."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"DiNicolantonio JJ, Tomek A. Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial. International Journal of Cardiology. 2013; 168: 4076\u20134080.","DOI":"10.1016\/j.ijcard.2013.07.020."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials\u2013common patterns in TRITON, RECORD, and PLATO? Thrombosis and Haemostasis. 2012; 108: 412\u2013414.","DOI":"10.1160\/TH12-04-0251."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Verheugt FWA. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Editorial on Serebruany, Atar: \u2018Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials\u2013common patterns in TRITON, RECORD, and PLATO?\u2019 (Thromb Haemost 2012; 108.3). Thrombosis and Haemostasis. 2012; 108: 410\u2013411.","DOI":"10.1160\/TH12-06-0435."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Doshi P. Doubts over landmark heart drug trial: ticagrelor PLATO study. BMJ (Clinical Research Ed.). 2024; 387: q2550.","DOI":"10.1136\/bmj.q2550."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Erviti J, Wright J, Bassett K, Ben-Eltriki M, Jauca C, Saiz LC, et al. Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data. BMJ Open. 2022; 12: e060172.","DOI":"10.1136\/bmjopen-2021-060172."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Dechartres A, Boutron I, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. Journal of Clinical Epidemiology. 2009; 62: 695\u2013702.","DOI":"10.1016\/j.jclinepi.2008.09.011."},{"key":"ref16","unstructured":"Perez-Campos E, Casta\u00f1eda-Hern\u00e1ndez G, Cabrera-Fuentes HA. Rapid Response: \u201cUrgent Call for Regulatory Reforms in Mexico Following PLATO Trial Findings\u201d. [Rapid response to Doubts over landmark heart drug trial: Ticagrelor PLATO study]. BMJ (Clinical research ed.). 2025. Available at: https:\/\/www.bmj.com\/content\/387\/bmj.q2550\/rr-1. (Accessed: 24 January 2025)."}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/26\/4\/10.31083\/RCM36733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T06:58:33Z","timestamp":1745909913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/26\/4\/10.31083\/RCM36733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"alternative-id":["S1530-6550(25)01789-2"],"URL":"https:\/\/doi.org\/10.31083\/rcm36733","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]},"article-number":"36733"}}